(S)-1-phenylpentan-2-ol | 198642-79-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-1-phenylpentan-2-ol
• 英文别名: (+)-1-phenyl-2-pentanol；(2S)-1-phenylpentan-2-ol；(S)-1-phenyl-2-pentanol
• CAS: 198642-79-4
• 化学式: C₁₁H₁₆O
• 分子量: 164.247
• InChiKey: FCURFTSXOIATDW-NSHDSACASA-N

物化性质

• 沸点：
  251.3±0.0 °C(Predicted)
• 密度：
  0.968±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (S)-1-phenylpentan-2-ol 在 三氧化硫吡啶 、 二甲基亚砜 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 甲苯 为溶剂， 生成 ((S)-1-Formyl-pentyl)-carbamic acid (S)-1-benzyl-butyl ester
  参考文献：
  名称：

  Exploration of the P2–P3 SAR of aldehyde cathepsin K inhibitors

  摘要：

  The synthesis and biological activity of a series of aldehyde inhibitors of cathepsin K are reported. Exploration of the properties of the S-2 and S-3 subsites with a series of carbamate derivatized norleucine aldehydes substituted at the P-2 and P-3 positions afforded analogs with cathepsin K IC(50)s between 600 nM and 130 pM. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.084
• 作为产物：
  描述：

  (1E)-1,4-pentadienylbenzene 在 溶剂黄146 作用下， 以 乙醚 为溶剂， 反应 0.17h， 生成 (S)-1-phenylpentan-2-ol
  参考文献：
  名称：

  Chiral Synthesis via Organoboranes. 48. Efficient Synthesis of Trans-Fused Bicyclic and Cyclic Ketones and Secondary Alcohols in High Optical Purities via Asymmetric Cyclic Hydroboration with Isopinocampheylchloroborane Etherate

  摘要：

  Highly stereo- and enantioselective annelation has been achieved for the synthesis of trans-fused bicyclic and cyclic ketones via the asymmetric cyclic hydroboration of suitable cyclic dienes, such as 1-allyl-1-cycloalkenes or 1-vinyl-1-cycloalkenes and appropriate acyclic 1,4-dienes, respectively, with enantiomerically pure isopinocampheylchloroborane etherate (IpcBHCl . Et2O). The IpcBHCl . Et2O (an 86-90% equilibrium mixture) was readily synthesized by the reaction of an equivalent amount of hydrochloric acid in ethyl ether (Et2O) with optically pure isopinocampheylborane (IpcBH(2)). The hydroboration of the terminal double bond of a representative diene with IpcBHCl . Et2O readily provided the corresponding isopinocampheylalkylchloroborane (IpcRBCl). Subsequent, hydridation of the IpcRBCl with lithium aluminum hydride (LAH, 0.25 equiv) at -20 or -25 degrees C generated the intermediate isopinocampheylalkylborane (IpcRBH) almost instantly, which then underwent a rapid stereospecific and enantioselective intramolecular cyclic hydroboration to provide the intermediate cyclic trialkylborane. This trialkylborane, on treatment with an aldehyde, liberated the optically pure auxiliary as a-pinene (readily recovered for recycle) to provide the corresponding cyclic borinate ester. This ester reacted smoothly with alpha,alpha-dichloromethyl methyl ether (DCME) in the presence of a hindered base (the DCME reaction) to yield, after oxidation with buffered hydrogen peroxide, the trans-fused bicyclic or cyclic ketone in high enantiomeric excess (ee). In another improved approach, in situ generated IpcBHCl . Et2O, from the reduction of isopinocampheyldichloroborane (IpcBCl(2)) with trimethylsilane (Me3SiH), in the presence of representative dienes in Et2O provided considerably improved optical yields of the bicyclic and cyclic ketones. The trialkylboranes obtained from suitable acyclic dienes can be easily protonolyzed to provide the secondary alcohols in high ee.

  DOI：

  10.1021/jo981040c

文献信息

• Substituted Cyclohexylamine Compounds
  申请人：EPIZYME, INC.

  公开号：US20200123142A1

  公开（公告）日：2020-04-23

  The present disclosure provides substituted cyclohexylamine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2a , R 2b , R 3a , R 3b , R 4 , R 5 , and R 7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

  本公开提供具有化学式（I）的替代环己胺化合物及其药用可接受的盐和溶剂化合物，其中R1、R2a、R2b、R3a、R3b、R4、R5和R7如规范中所定义。本公开还涉及使用化合物I的方法来治疗对SMYD蛋白如SMYD3或SMYD2阻断产生反应的疾病。本公开的化合物特别适用于治疗癌症。
• A General Method for the Synthesis of Nonracemic <i>trans</i>-Epoxides:  Concise Syntheses of <i>trans</i>-Epoxide-Containing Insect Sex Pheromones
  作者：Baldip Kang、Robert Britton

  DOI：10.1021/ol702273n

  日期：2007.11.1

  developed that provides rapid access to alkyl-, alkenyl-, alkynyl-, and phenyl-substituted trans-epoxides from aldehydes. This methodology has also been applied in concise and high-yielding syntheses of both trans-epoxide containing insect sex pheromones.

  已经开发了用于合成手性非外消旋反式环氧化物的通用方法，该方法提供了从醛类快速进入烷基，烯基，炔基和苯基取代的反式环氧化物的途径。该方法也已用于含有反式环氧化物的昆虫性信息素的简明和高产合成中。
• Recombinant porcine liver esterases, their use and a method for the production thereof
  申请人：——

  公开号：US20040161836A1

  公开（公告）日：2004-08-19

  The invention relates to biotechnologically expressible, enzymically active recombinant porcine liver esterases, to a biotechnological method for the preparation thereof and to the use thereof in organic synthesis. The monomeric subunits of recombinant porcine liver esterase are truncated at their C-terminal end, compared with naturally occurring porcine liver esterase subunits. Moreover, it has proved to be an additional advantage to truncate the N-terminal end as well.

  这项发明涉及生物技术表达的、具有酶活性的重组猪肝酯酶，以及一种用于制备该酶的生物技术方法，以及在有机合成中使用该酶的方法。重组猪肝酯酶的单体亚基在其C端与天然存在的猪肝酯酶亚基相比被截短。此外，证明将N端也截短是额外的优势。
• SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP1847533A1

  公开（公告）日：2007-10-24

  A compound represented by the general formula (I) or a salt thereof: [T represents oxygen atom and the like; V represents CH2 and the like; RO1 to RO4 represent hydrogen atom and the like; A represents a linear alkylene group or linear alkenylene group having 2 to 8 carbon atoms and the like; D represents carboxyl group and the like; X represents ethylene group, trimethylene group and the like; E represents -CH(OH)- group and the like; and W represent -U1-(RW1)(RW2)-U2-U3 group (U1 represents a single bond, an alkylene group having 1 to 4 carbon atoms and the like; RW1 and RW2 represent hydrogen atom and the like; U2 represents a single bond, an alkylene group having 1 to 4 carbon atoms and the like; and U3 represent an alkyl group having 1 to 8 carbon atoms and the like), or a residue of a carbon ring or heterocyclic compound], which can be utilized as an active ingredient of medicaments effective for prophylactic and/or therapeutic treatment of skeletal diseases such as osteoporosis and fracture, glaucoma, ulcerative colitis and the like.

  通式 (I) 所代表的化合物或其盐： [T 代表氧原子等；V 代表 CH2 等；RO1 至 RO4 代表氢原子等；A 代表具有 2 至 8 个碳原子的直链烯基或直链烯基等；D 代表羧基等；X 代表乙烯基、三亚甲基等；E 代表-CH(OH)- 基等；W 代表-U1-(RW1)(RW2)-U2-U3 基（U1 代表单键、具有 1 至 4 个碳原子的亚烷基等）；RW1 和 RW2 代表氢原子等；U2 代表单键、具有 1 至 4 个碳原子的亚烷基等；U3 代表具有 1 至 8 个碳原子的烷基等），或碳环或杂环化合物的残基]，可用作有效预防和/或治疗骨质疏松症和骨折等骨骼疾病、青光眼、溃疡性结肠炎等疾病的药物的活性成分。
• Isoxazole carboxamide compounds
  申请人：EPIZYME, INC.

  公开号：US10428029B2

  公开（公告）日：2019-10-01

  The present disclosure provides substituted isoxazole carboxamide compounds having Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, A, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

  本公开提供了具有式（I）的取代异噁唑羧酰胺化合物及其药学上可接受的盐和溶液，其中R1、R2、A、X和Z的定义如说明书所述。本公开还涉及使用式 I 的化合物治疗对 SMYD 蛋白如 SMYD3 或 SMYD2 的阻断有反应的紊乱。本公开的化合物尤其适用于治疗癌症。